clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-9-10-467-473clinmed-632Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESКардиоваскулярные эффекты психотропных препаратовCardiovascular eff ects of psychotropic drugsВарданянЯ. Т.VardanyanYa. Т.

Варданян Яна Тиграновна — студентка 6-го курса факультета фундаментальной медицины

119991, Москва

Yana Т. Vardanyan

119991, Moscow

yana.vardanyan.99@inbox.ruФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»РоссияLomonosov Moscow State UniversityRussian Federation2023131120231019-10467473Copyright © Варданян Я.Т., 20232023Варданян Я.Т.Vardanyan Y.Т.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/632

Исследования последних десятилетий указывают на то, что некоторые психотропные препараты вызывают повышенный риск развития аритмий и внезапной сердечной смерти. Многие антидепрессанты и антипсихотические препараты имеют аритмогенный потенциал и ассоциированы с удлинением интервала QT и развитием желудочковой аритмии по типу «пируэт», в то время как некоторые психотропные препараты связаны с изменениями ЭКГ по фенотипу синдрома Бругада и развитием полиморфных желудочковых аритмий.

Research over the past decade indicates that some psychotropic drugs increase the risk of developing arrhythmias and sudden cardiac death. Many antidepressants and antipsychotic drugs have arrhythmogenic potential and are associated with QT interval prolongation and development of ventricular arrhythmia of the “torsades de pointes” type, while some psychotropic drugs are associated with changes in ECG phenotype of Brugada syndrome and development of polymorphic ventricular arrhythmias.

психотропные препаратыаритмияантидепрессантывнезапная сердечная смертьсиндром Бругадаинтервал QTpsychotropic drugsarrhythmiaantidepressantssudden cardiac deathBrugada syndromeQT intervalReferencesBuckley N.A., Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000;23(3):215–28. DOI: 10.2165/00002018-200023030-00004Buckley N.A., Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000;23(3):215–28. DOI: 10.2165/00002018-200023030-00004Herxheimer A., Healy D. Arrhythmias and sudden death in patients taking antipsychotic drugs. BMJ. 2002;325(7375):1253–1254. DOI: 10.1136/BMJ.325.7375.1253Herxheimer A., Healy D. Arrhythmias and sudden death in patients taking antipsychotic drugs. BMJ. 2002;325(7375):1253–1254. DOI: 10.1136/BMJ.325.7375.1253Thioridazine hydrochloride (mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. PubMed. URL: https://pubmed.ncbi.nlm.nih.gov/14045347/ (accessed Nov. 30, 2021)Thioridazine hydrochloride (mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. PubMed. URL: https://pubmed.ncbi.nlm.nih.gov/14045347/ (accessed Nov. 30, 2021)Yuhas J. et al. Patients’ attitudes and perceptions of implantable cardioverter-defi brillators: potential barriers to appropriate primary prophylaxis. Pacing Clin. Electrophysiol. 2012;35(10):1179–1187. DOI: 10.1111/J.1540-8159.2012.03497.XYuhas J. et al. Patients’ attitudes and perceptions of implantable cardioverter-defi brillators: potential barriers to appropriate primary prophylaxis. Pacing Clin. Electrophysiol. 2012;35(10):1179–1187. DOI: 10.1111/J.1540-8159.2012.03497.XSicouri S., Antzelevitch C. Clinical Reviews: Drugs and Devices Drug-induced Long QT Syndrome and Torsade de Pointes by Antidepressant and Antipsychotic Agents Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Cit. Arrhythmia Electrophysiol. Rev. 2018;7(3):199–209. DOI: 10.15420/aer.2018.29.2Sicouri S., Antzelevitch C. Clinical Reviews: Drugs and Devices Drug-induced Long QT Syndrome and Torsade de Pointes by Antidepressant and Antipsychotic Agents Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Cit. Arrhythmia Electrophysiol. Rev. 2018;7(3):199–209. DOI: 10.15420/aer.2018.29.2Brugada P., Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J. Am. Coll. Cardiol. 1992;20(6):1391–1396. DOI: 10.1016/0735-1097(92)90253-JBrugada P., Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J. Am. Coll. Cardiol. 1992;20(6):1391–1396. DOI: 10.1016/0735-1097(92)90253-JWilde A.A.M. et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106(19):2514–2519. DOI: 10.1161/01.CIR.0000034169.45752.4AWilde A.A.M. et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106(19):2514–2519. DOI: 10.1161/01.CIR.0000034169.45752.4AFunk M.C. et al. QTc Prolongation and Psychotropic Medications. Am. J. Psychiatry. 2020;177(3):273–274. DOI: 10.1176/APPI.AJP.2019.1760501Funk M.C. et al. QTc Prolongation and Psychotropic Medications. Am. J. Psychiatry. 2020;177(3):273–274. DOI: 10.1176/APPI.AJP.2019.1760501Teply R.M., Packard K.A., White N.D., Hilleman D.E., DiNicolantonio J.J. Treatment of Depression in Patients with Concomitant Cardiac Disease. Prog. Cardiovasc. Dis. 2016:58(5):514–528. DOI: 10.1016/J.PCAD.2015.11.003Teply R.M., Packard K.A., White N.D., Hilleman D.E., DiNicolantonio J.J. Treatment of Depression in Patients with Concomitant Cardiac Disease. Prog. Cardiovasc. Dis. 2016:58(5):514–528. DOI: 10.1016/J.PCAD.2015.11.003Gibbons R.D., Hur K., Bhaumik D.K., Mann J.J. The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry. 2005:62(2):165–172. DOI: 10.1001/archpsyc.62.2.165Gibbons R.D., Hur K., Bhaumik D.K., Mann J.J. The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry. 2005:62(2):165–172. DOI: 10.1001/archpsyc.62.2.165Carvalho A.F., Sharma M.S., Brunoni A.R., Vieta E., Fava G.A. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother. Psychosom. 2016:85(5):270–288. DOI: 10.1159/000447034Carvalho A.F., Sharma M.S., Brunoni A.R., Vieta E., Fava G.A. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother. Psychosom. 2016:85(5):270–288. DOI: 10.1159/000447034Bolognesi R., Tsialtas D., Vasini P., Conti M., Manca C. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am. J. Cardiol. 1997:79(2):242– 245. DOI: 10.1016/S0002-9149(96)00727-8Bolognesi R., Tsialtas D., Vasini P., Conti M., Manca C. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am. J. Cardiol. 1997:79(2):242– 245. DOI: 10.1016/S0002-9149(96)00727-8Darbar D., Yang T., Churchwell K., Wilde A.A.M., Roden D.M. Un masking of brugada syndrome by lithium. Circulation. 2005:112(11):1527–1531. DOI: 10.1161/CIRCULATIONAHA.105.548487Darbar D., Yang T., Churchwell K., Wilde A.A.M., Roden D.M. Un masking of brugada syndrome by lithium. Circulation. 2005:112(11):1527–1531. DOI: 10.1161/CIRCULATIONAHA.105.548487Danielsson B., Collin J., Jonasdottir Bergman G., Borg N., Salmi P., Fastbom J. Antidepressants and antipsychotics classifi ed with torsades de pointes arrhythmia risk and mortality in older adults — a Swedish nationwide study. Br. J. Clin. Pharmacol. 2016:81(4):773. DOI: 10.1111/BCP.12829Danielsson B., Collin J., Jonasdottir Bergman G., Borg N., Salmi P., Fastbom J. Antidepressants and antipsychotics classifi ed with torsades de pointes arrhythmia risk and mortality in older adults — a Swedish nationwide study. Br. J. Clin. Pharmacol. 2016:81(4):773. DOI: 10.1111/BCP.12829O’Regan C., Kenny R.A., Cronin H., Finucane C., Kearney P.M. Antidepressants strongly infl uence the relationship between depression and heart rate variability: fi ndings from The Irish Longitudinal Study on Ageing (TILDA). Psychol. Med. 2015:45(3):623–636. DOI: 10.1017/S0033291714001767O’Regan C., Kenny R.A., Cronin H., Finucane C., Kearney P.M. Antidepressants strongly infl uence the relationship between depression and heart rate variability: fi ndings from The Irish Longitudinal Study on Ageing (TILDA). Psychol. Med. 2015:45(3):623–636. DOI: 10.1017/S0033291714001767Kemp A.H. et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am. J. Psychiatry. 2014:171(12):1328–1334. DOI: 10.1176/APPI.AJP.2014.13121605Kemp A.H. et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am. J. Psychiatry. 2014:171(12):1328–1334. DOI: 10.1176/APPI.AJP.2014.13121605Kemp A.H. et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am. J. Psychiatry. 2014:171(12):1328–1334. DOI: 10.1176/APPI.AJP.2014.13121605Kemp A.H. et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am. J. Psychiatry. 2014:171(12):1328–1334. DOI: 10.1176/APPI.AJP.2014.13121605Taylor C.B. Depression, heart rate related variables and cardiovascular disease. Int. J. Psychophysiol. 2010:78(1):80–88. DOI: 10.1016/J.IJPSYCHO.2010.04.006Taylor C.B. Depression, heart rate related variables and cardiovascular disease. Int. J. Psychophysiol. 2010:78(1):80–88. DOI: 10.1016/J.IJPSYCHO.2010.04.006Behlke L.M., Lenze E.J., Carney R.M. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020:34(11):1133– 1147. DOI: 10.1007/S40263-020-00763-ZBehlke L.M., Lenze E.J., Carney R.M. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020:34(11):1133– 1147. DOI: 10.1007/S40263-020-00763-ZUpward J., Edwards J., Goldie A., and Waller D. Comparative effects of fl uoxetine and amitriptyline on cardiac function. Br. J. Clin. Pharmacol. 1988:26(4):399–402. DOI: 10.1111/J.1365-2125.1988.TB03397.XUpward J., Edwards J., Goldie A., and Waller D. Comparative effects of fl uoxetine and amitriptyline on cardiac function. Br. J. Clin. Pharmacol. 1988:26(4):399–402. DOI: 10.1111/J.1365-2125.1988.TB03397.XFunk K.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann. Pharmacother. 2013:47(10):1330–1341. DOI: 10.1177/1060028013501994Funk K.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann. Pharmacother. 2013:47(10):1330–1341. DOI: 10.1177/1060028013501994Sicouri S., Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol. Rev. 2018:7(3):199–209. DOI: 10.15420/AER.2018.29.2Sicouri S., Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol. Rev. 2018:7(3):199–209. DOI: 10.15420/AER.2018.29.2Cubeddu L. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr. Cardiol. Rev. 2016:12(2):141–154. DOI: 10.2174/1573403X12666160301120217Cubeddu L. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr. Cardiol. Rev. 2016:12(2):141–154. DOI: 10.2174/1573403X12666160301120217Seo J.S. et al. Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clin. Psychopharmacol. Neurosci. 2021:19(4):751–772. DOI: 10.9758/cpn.2021.19.4.751Seo J.S. et al. Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clin. Psychopharmacol. Neurosci. 2021:19(4):751–772. DOI: 10.9758/cpn.2021.19.4.751Darowski A., Chambers S.A.C.F., Chambers D.J., Antidepressants and falls in the elderly. Drugs Aging. 2009:26(5):381–394. DOI: 10.2165/00002512-200926050-00002Darowski A., Chambers S.A.C.F., Chambers D.J., Antidepressants and falls in the elderly. Drugs Aging. 2009:26(5):381–394. DOI: 10.2165/00002512-200926050-00002Cherin P., Colvez A., De Periere G.D., Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J. Clin. Epidemiol. 1997:50(3):313–320. DOI: 10.1016/S0895-4356(96)00385-XCherin P., Colvez A., De Periere G.D., Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J. Clin. Epidemiol. 1997:50(3):313–320. DOI: 10.1016/S0895-4356(96)00385-XPehrson A.L. et al. Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for effi cacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur. J. Pharmacol. 2015:753:19–31. DOI: 10.1016/J.EJPHAR.2014.07.044Pehrson A.L. et al. Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for effi cacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur. J. Pharmacol. 2015:753:19–31. DOI: 10.1016/J.EJPHAR.2014.07.044Jasiak N.M., Bostwick J.R. Risk of QT/QTc prolongation among newer non-SSRI antidepressants.Ann. Pharmacother. 2014:48(12):1620– 1628. DOI: 10.1177/1060028014550645Jasiak N.M., Bostwick J.R. Risk of QT/QTc prolongation among newer non-SSRI antidepressants.Ann. Pharmacother. 2014:48(12):1620– 1628. DOI: 10.1177/1060028014550645Whiskey E. Taylor D. A review of the adverse eff ects and safety of noradrenergic antidepressants. J. Psychopharmacol. 2013:27(8):732– 739. DOI: 10.1177/0269881113492027Whiskey E. Taylor D. A review of the adverse eff ects and safety of noradrenergic antidepressants. J. Psychopharmacol. 2013:27(8):732– 739. DOI: 10.1177/0269881113492027Johnson E.M. et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry. 2006:14(9):796–802. DOI: 10.1097/01.JGP.0000204328.50105.B3Johnson E.M. et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry. 2006:14(9):796–802. DOI: 10.1097/01.JGP.0000204328.50105.B3Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C., Detke M.J. Cardiovascular profi le of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 2005:25(2):132–140. DOI: 10.1097/01.JCP.0000155815.44338.95Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C., Detke M.J. Cardiovascular profi le of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 2005:25(2):132–140. DOI: 10.1097/01.JCP.0000155815.44338.95Asnis G.M., Henderson M.A. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr. Dis. Treat. 2015:11:125–135. DOI: 10.2147/NDT.S54710Asnis G.M., Henderson M.A. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr. Dis. Treat. 2015:11:125–135. DOI: 10.2147/NDT.S54710Goldgran-Toledano D., Sideris G., Kevorkian J.-P. Overdose of cyclic antidepressants and the Brugada syndrome. N. Engl. J. Med. 2002:346(20):1591–1592. DOI: 10.1056/NEJM200205163462020Goldgran-Toledano D., Sideris G., Kevorkian J.-P. Overdose of cyclic antidepressants and the Brugada syndrome. N. Engl. J. Med. 2002:346(20):1591–1592. DOI: 10.1056/NEJM200205163462020De La Torre B.R. et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit. 2001:23(4):435–440. DOI: 10.1097/00007691-200108000-00019De La Torre B.R. et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit. 2001:23(4):435–440. DOI: 10.1097/00007691-200108000-00019Glassman A.H. Cardiovascular effects of tricyclic antidepressants. Annu. Rev. Med. 1984:35:503–511. DOI: 10.1146/ANNUREV.ME.35.020184.002443Glassman A.H. Cardiovascular effects of tricyclic antidepressants. Annu. Rev. Med. 1984:35:503–511. DOI: 10.1146/ANNUREV.ME.35.020184.002443Beach S.R. et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J. Clin. Psychiatry. 2014:75(5):e441–449. DOI: 10.4088/JCP.13R08672Beach S.R. et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J. Clin. Psychiatry. 2014:75(5):e441–449. DOI: 10.4088/JCP.13R08672Vieweg W.V.R., Wood M.A. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004:45(5):371–377. DOI: 10.1176/APPI.PSY.45.5.371Vieweg W.V.R., Wood M.A. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004:45(5):371–377. DOI: 10.1176/APPI.PSY.45.5.371Wenzel-Seifert K., Wittmann M., Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch. Arztebl. Int. 2011:108(41):687–693. DOI: 10.3238/ARZTEBL.2011.0687Wenzel-Seifert K., Wittmann M., Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch. Arztebl. Int. 2011:108(41):687–693. DOI: 10.3238/ARZTEBL.2011.0687Nelson J.C., Pritchett Y.L., Martynov O., Yu J.Y., Mallinckrodt C.H., Detke M.J. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim. Care Companion J. Clin. Psychiatry. 2006:8(4):212–219. DOI: 10.4088/PCC.V08N0404Nelson J.C., Pritchett Y.L., Martynov O., Yu J.Y., Mallinckrodt C.H., Detke M.J. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim. Care Companion J. Clin. Psychiatry. 2006:8(4):212–219. DOI: 10.4088/PCC.V08N0404Alampay M.M., Haigney M.C., Flanagan M.C., Perito R.M., Love K.M., Grammer G.G., Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope. Mayo Clin. Proc. 2014:89(11):1584–1587. DOI: 10.1016/J.MAYOCP.2014.08.010Alampay M.M., Haigney M.C., Flanagan M.C., Perito R.M., Love K.M., Grammer G.G., Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope. Mayo Clin. Proc. 2014:89(11):1584–1587. DOI: 10.1016/J.MAYOCP.2014.08.010Rouleau F. et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J. Cardiovasc. Electrophysiol. 2001:12(1):61–65. DOI: 10.1046/J.1540-8167.2001.00061.XRouleau F. et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J. Cardiovasc. Electrophysiol. 2001:12(1):61–65. DOI: 10.1046/J.1540-8167.2001.00061.XChaw B.J.W., Gallab M., Birnie D. Brugada syndrome precipitated by a tricyclic antidepressant. Heart. 2005:91(5):651. DOI: 10.1136/HRT.2004.049593Chaw B.J.W., Gallab M., Birnie D. Brugada syndrome precipitated by a tricyclic antidepressant. Heart. 2005:91(5):651. DOI: 10.1136/HRT.2004.049593Babaliaros V.C., Hurst J.W. Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the administration of desipramine. Clin. Cardiol. 2002:25(8):395–398. DOI: 10.1002/CLC.4950250809Babaliaros V.C., Hurst J.W. Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the administration of desipramine. Clin. Cardiol. 2002:25(8):395–398. DOI: 10.1002/CLC.4950250809Tada H., Sticherling C., Oral H., Morady F. Brugada syndrome mimicked by tricyclic antidepressant overdose. J. Cardiovasc. Electrophysiol. 2001;12(2):275. DOI: 10.1046/J.1540-8167.2001.00275.XTada H., Sticherling C., Oral H., Morady F. Brugada syndrome mimicked by tricyclic antidepressant overdose. J. Cardiovasc. Electrophysiol. 2001;12(2):275. DOI: 10.1046/J.1540-8167.2001.00275.XBigwood B., Galler D., Amir N., Smith W. Brugada syndrome following tricyclic antidepressant overdose. Anaesth. Intensive Care. 2005:33(2):266–270. DOI: 10.1177/0310057X0503300219Bigwood B., Galler D., Amir N., Smith W. Brugada syndrome following tricyclic antidepressant overdose. Anaesth. Intensive Care. 2005:33(2):266–270. DOI: 10.1177/0310057X0503300219Sicouri S., Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol. Rev. 2018:7(3):199–209. DOI: 10.15420/AER.2018.29.2Sicouri S., Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol. Rev. 2018:7(3):199–209. DOI: 10.15420/AER.2018.29.2Carrà G. et al. First-generation antipsychotics and QTc: any role for mediating variables? Hum. Psychopharmacol. 2016:31(4):313–318. DOI: 10.1002/HUP.2540Carrà G. et al. First-generation antipsychotics and QTc: any role for mediating variables? Hum. Psychopharmacol. 2016:31(4):313–318. DOI: 10.1002/HUP.2540Wu C.S., Tsai Y.T., Tsai H.J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J. Am. Heart Assoc. 2015:4(2). DOI: 10.1161/JAHA.114.001568Wu C.S., Tsai Y.T., Tsai H.J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J. Am. Heart Assoc. 2015:4(2). DOI: 10.1161/JAHA.114.001568Beach S.R., Celano C.M., Noseworthy P.A., Januzzi J.L., Huffman J.C. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013:54(1):1–13. DOI: 10.1016/J.PSYM.2012.11.001Beach S.R., Celano C.M., Noseworthy P.A., Januzzi J.L., Huffman J.C. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013:54(1):1–13. DOI: 10.1016/J.PSYM.2012.11.001Harrigan E.P. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 2004:24(1):62–69. DOI: 10.1097/01.JCP.0000104913.75206.62Harrigan E.P. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 2004:24(1):62–69. DOI: 10.1097/01.JCP.0000104913.75206.62Chong S.A., Mythily A., Lum A., Goh H.Y., Chan Y.H. Prolonged QTc intervals in medicated patients with schizophrenia. Hum. Psychopharmacol. 2003:18(8):647–649. DOI: 10.1002/HUP.540Chong S.A., Mythily A., Lum A., Goh H.Y., Chan Y.H. Prolonged QTc intervals in medicated patients with schizophrenia. Hum. Psychopharmacol. 2003:18(8):647–649. DOI: 10.1002/HUP.540Glassman A.H., Bigger J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. 2001:158(11):1774–1782. DOI: 10.1176/APPI.AJP.158.11.1774Glassman A.H., Bigger J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. 2001:158(11):1774–1782. DOI: 10.1176/APPI.AJP.158.11.1774Thomas D. et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol. 2003:139(3):567–574. DOI: 10.1038/SJ.BJP.0705283Thomas D. et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol. 2003:139(3):567–574. DOI: 10.1038/SJ.BJP.0705283Zeuli J.D., Wilson J.W., Estes L.L. Effect of combined fl uoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob. Agents Chemother. 2013:57(3):1121–1127. DOI: 10.1128/AAC.00958-12Zeuli J.D., Wilson J.W., Estes L.L. Effect of combined fl uoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob. Agents Chemother. 2013:57(3):1121–1127. DOI: 10.1128/AAC.00958-12Leucht S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England). 2013:382(9896):951–962. DOI: 10.1016/S0140-6736(13)60733-3Leucht S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England). 2013:382(9896):951–962. DOI: 10.1016/S0140-6736(13)60733-3Beach S.R. et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018:59(2):105–122. DOI: 10.1016/J.PSYM.2017.10.009Beach S.R. et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018:59(2):105–122. DOI: 10.1016/J.PSYM.2017.10.009Spyker D.A., Voloshko P., Heyman E.R., Cassella J.V. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J. Clin. Pharmacol. 2014:54(6):665–674. DOI: 10.1002/JCPH.257Spyker D.A., Voloshko P., Heyman E.R., Cassella J.V. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J. Clin. Pharmacol. 2014:54(6):665–674. DOI: 10.1002/JCPH.257Cassella J.V., Spyker D.A., Yeung P.P. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2015:53(11):963–971. DOI: 10.5414/CP202457Cassella J.V., Spyker D.A., Yeung P.P. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2015:53(11):963–971. DOI: 10.5414/CP202457Tracz K., Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br. J. Clin. Pharmacol. 2015:79(4):669–676. DOI: 10.1111/BCP.12527Tracz K., Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br. J. Clin. Pharmacol. 2015:79(4):669–676. DOI: 10.1111/BCP.12527Polcwiartek C. et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015:232(18):3297– 3308. DOI: 10.1007/S00213-015-4024-9Polcwiartek C. et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015:232(18):3297– 3308. DOI: 10.1007/S00213-015-4024-9Goff D.C. et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J. Clin. Psychopharmacol. 2013:33(4):485–490. DOI: 10.1097/JCP.0B013E3182977308Goff D.C. et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J. Clin. Psychopharmacol. 2013:33(4):485–490. DOI: 10.1097/JCP.0B013E3182977308Camm A.J. et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs. 2012:26(4):351– 365. DOI: 10.2165/11599010-000000000-00000Camm A.J. et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs. 2012:26(4):351– 365. DOI: 10.2165/11599010-000000000-00000Edinoff A. et al. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults. Psychopharmacol. Bull. 2020:50(4):83–117. URL: https://pubmed.ncbi.nlm.nih.gov/33012874/. Accessed: Nov. 30, 2021.Edinoff A. et al. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults. Psychopharmacol. Bull. 2020:50(4):83–117. URL: https://pubmed.ncbi.nlm.nih.gov/33012874/. Accessed: Nov. 30, 2021.

The authors declare that there are no conflicts of interest present.